发生了什么？_老虎社区_美港股上老虎

发生了什么？

港股异动 | 医药股延续跌势，诺诚健华跌超11%，荣昌生物跌超10%

10月10日，港股医药股再度走低，$诺诚健华$、$圣诺医药-B$跌超11%，$荣昌生物$跌超10%，$歌礼制药-B$、$维亚生物$跌超8%。该行称，ESMO大会将于今年10月中下旬举行，建议重点关注$康方生物$、$科伦博泰$、$荣昌生物$、$恒瑞医药$等有重磅数据读出的公司。9月港股医药板块表现相对平淡，10月起，随着行业催化剂增多，行情有望重启。

港股异动 | 医药股延续跌势，诺诚健华跌超11%，荣昌生物跌超10%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":487711173226968,"tweetId":"487711173226968","gmtCreate":1760078810773,"gmtModify":1760078812931,"author":{"id":4185548511580342,"idStr":"4185548511580342","authorId":4185548511580342,"authorIdStr":"4185548511580342","name":"秋水镜贤","avatar":"https://static.tigerbbs.com/b3e80a2b71ce58f1f18648b34b17434c","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>发生了什么？</p></body></html>","htmlText":"<html><head></head><body><p>发生了什么？</p></body></html>","text":"发生了什么？","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/487711173226968","repostId":2574214422,"repostType":2,"repost":{"id":"2574214422","kind":"news","pubTimestamp":1760078435,"share":"https://www.laohu8.com/m/news/2574214422?lang=&edition=full","pubTime":"2025-10-10 14:40","market":"fut","language":"zh","title":"港股异动 | 医药股延续跌势，诺诚健华跌超11%，荣昌生物跌超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2574214422","media":"智通财经","summary":"10月10日，港股医药股再度走低，$诺诚健华$、$圣诺医药-B$跌超11%，$荣昌生物$跌超10%，$歌礼制药-B$、$维亚生物$跌超8%。该行称，ESMO大会将于今年10月中下旬举行，建议重点关注$康方生物$、$科伦博泰$、$荣昌生物$、$恒瑞医药$等有重磅数据读出的公司。9月港股医药板块表现相对平淡，10月起，随着行业催化剂增多，行情有望重启。","content":"<html><head></head><body><p>10月10日，港股医药股再度走低，<a href=\"https://laohu8.com/S/09969\">诺诚健华</a>、<a href=\"https://laohu8.com/S/02257\">圣诺医药-B</a>跌超11%，<a href=\"https://laohu8.com/S/09995\">荣昌生物</a>跌超10%，<a href=\"https://laohu8.com/S/01672\">歌礼制药-B</a>、<a href=\"https://laohu8.com/S/01873\">维亚生物</a>跌超8%。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/4e17954dbc42b8af7b479c23fe837d48\" tg-width=\"904\" tg-height=\"641\"/></p><p><a href=\"https://laohu8.com/S/03329\">交银国际</a>表示，9月以来，内资通过港股通持有医药股的比例持续增加，而外资持仓则从年中开始略有回落，但内外资加大创新药布局的大方向不变。该行称，ESMO大会将于今年10月中下旬举行，建议重点关注<a href=\"https://laohu8.com/S/09926\">康方生物</a>、<a href=\"https://laohu8.com/S/06990\">科伦博泰</a>、<a href=\"https://laohu8.com/S/09995\">荣昌生物</a>、<a href=\"https://laohu8.com/S/600276\">恒瑞医药</a>等有重磅数据读出的公司。9月港股医药板块表现相对平淡，10月起，随着行业催化剂增多（各项学术大会、利好政策落地），行情有望重启。</p><p>东莞证券研报指出，近期，医药生物板块持续跑输同期沪深300指数，此前部分涨幅较大的创新药公司迎来回调，受美国降息预期走强以及投融资数据改善，医疗研发外包板块持续走强，目前已经进入业绩真空期，后续建议关注创新药等有BD预期催化的板块投资机会。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 医药股延续跌势，诺诚健华跌超11%，荣昌生物跌超10%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 医药股延续跌势，诺诚健华跌超11%，荣昌生物跌超10%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-10 14:40 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1353539.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10月10日，港股医药股再度走低，诺诚健华、圣诺医药-B跌超11%，荣昌生物跌超10%，歌礼制药-B、维亚生物跌超8%。交银国际表示，9月以来，内资通过港股通持有医药股的比例持续增加，而外资持仓则从年中开始略有回落，但内外资加大创新药布局的大方向不变。该行称，ESMO大会将于今年10月中下旬举行，建议重点关注康方生物、科伦博泰、荣昌生物、恒瑞医药等有重磅数据读出的公司。9月港股医药板块表现相对平淡...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1353539.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","relate_stocks":{"BK1141":"生命科学工具和服务","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","BK4614":"Manus概念股","09995":"荣昌生物","BK0239":"医药制造","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","BK1515":"抗疫概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK1576":"医药外包概念","BK1161":"生物科技","BK1574":"生物医药B类股","09969":"诺诚健华","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC"},"source_url":"http://www.zhitongcaijing.com/content/detail/1353539.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2574214422","content_text":"10月10日，港股医药股再度走低，诺诚健华、圣诺医药-B跌超11%，荣昌生物跌超10%，歌礼制药-B、维亚生物跌超8%。交银国际表示，9月以来，内资通过港股通持有医药股的比例持续增加，而外资持仓则从年中开始略有回落，但内外资加大创新药布局的大方向不变。该行称，ESMO大会将于今年10月中下旬举行，建议重点关注康方生物、科伦博泰、荣昌生物、恒瑞医药等有重磅数据读出的公司。9月港股医药板块表现相对平淡，10月起，随着行业催化剂增多（各项学术大会、利好政策落地），行情有望重启。东莞证券研报指出，近期，医药生物板块持续跑输同期沪深300指数，此前部分涨幅较大的创新药公司迎来回调，受美国降息预期走强以及投融资数据改善，医疗研发外包板块持续走强，目前已经进入业绩真空期，后续建议关注创新药等有BD预期催化的板块投资机会。","news_type":1,"symbols_score_info":{"09995":1.1,"09969":1.1}},"isVote":1,"tweetType":1,"viewCount":362,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":11,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}